Results 81 to 90 of about 181,836 (188)
The evaluation of approaches to the treatment of myasthenia gravis.
Medičnì Perspektivi, 2019 Myasthenia gravis is a relatively rare autoimmune disease with an undetermined aetiology which affects neuromuscular junctions. Currently, the following approaches to the treatment of myasthenia gravis are mainly distinguished: symptomatic treatment with
O. I. Kalbus +4 more
doaj +1 more source
Muscle &Nerve, Volume 74, Issue S1, Page S76-S83, September 2026.ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza +6 more
wiley +1 more source
Treatment of Ocular Myasthenia Gravis
, 2019 Myasthenia gravis is caused by pathogenic autoantibodies to the postsynaptic neuromuscular junction. Clinically, this may affect any of the skeletal muscles causing variable weakness, which worsens with continued muscle activity. Ocular myasthenia gravis
Michael Lee
core
Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative Study
Muscle &Nerve, Volume 74, Issue S1, Page S124-S131, September 2026.ABSTRACT Introduction/Aims The burden of myasthenia gravis (MG) is often underestimated, and studies usually focus on the symptom burden. However, treatment‐related adverse events also contribute to patients' burdens and affect their treatment decisions.
Meg Mendoza +6 more
wiley +1 more source
The Anti-Acetylcholine Receptor Antibody Test in Suspected Ocular Myasthenia Gravis
Journal of Ophthalmology, 2014 Aim. To estimate the clinical significance of anti-acetylcholine receptor antibody (anti-AChR-Ab) levels in suspected ocular myasthenia gravis. Methods. In total, 144 patients complaining of fluctuating diplopia and ptosis were evaluated for serum levels
Jung Jin Lee +2 more
doaj +1 more source
IgG Subclass (IgG1‐4) and IgA Autoantibody Profiles Against Muscle‐Specific Kinase in a Greek Cohort
Muscle &Nerve, Volume 74, Issue S1, Page S132-S141, September 2026.ABSTRACT Introduction/Aims Muscle‐specific kinase myasthenia gravis (MuSK‐MG) is an autoimmune neuromuscular disorder predominantly mediated by IgG4 autoantibodies disrupting MuSK signaling. The contribution of other isotypes remains incompletely defined. We characterized the serological profile of a Greek cohort of MuSK‐MG patients.
Sofia‐Natsοuko Gkotzamani +22 more
wiley +1 more source
Ocular myasthenia gravis: case report [PDF]
, 2020 Department of Ophthalmology and Optometry, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020Background.
Braicov, Daniela
core +1 more source
Muscle &Nerve, Volume 74, Issue S1, Page S97-S107, September 2026.ABSTRACT Urinary dysfunction has been reported in association with myasthenic syndromes, including myasthenia gravis (MG), Lambert–Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS), but evidence regarding its prevalence, clinical impact, pathophysiology, and management remains limited.
Julia M. Augustin +13 more
wiley +1 more source
, 2006 Poster, "Neoplasia Associated Ocular Myasthenia Gravis: Primary Renal Tumor in Two Patients with Newly Diagnosed Ocular Myasthenia ...
Susan Andracchi
core